

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

RESUMPTION OF TRADING IN THE A SHARES OF THE COMPANY

This announcement is made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”).

Reference is made to the announcement of the Company dated 22 December 2017 (the “**Previous Announcement**”) in relation to a very substantial acquisition of the Company.

In the Previous Announcement, it was disclosed, among other things, that trading in the A Shares had been suspended since 31 October 2017 and further announcement would be made by the Company on the Shanghai Stock Exchange upon the resumption of trading in the A Shares on the Shanghai Stock Exchange in due course.

The Company hereby announces that it has published an announcement dated 5 January 2018 on the Shanghai Stock Exchange announcing, among other things, that the trading of A Shares on the Shanghai Stock Exchange will resume with effect from 8 January 2018.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 5 January 2018

As at the date of this announcement, the board of directors of the Company comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.